While the new Alzheimer’s disease medicine Leqembi has generated lots of buzz since its debut this year, one research team is investigating whether the medicine holds promise in preventing disease progression before any Alzheimer’s symptoms are evident.

In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky talks with the study lead, Reisa Sperling, M.D., to learn more. 

To learn more about the topics in this episode: 

• Eisai, Biogen's injectable Leqembi clears toxic protein in Alzheimer's disease. What about safety?
• 'The Top Line': Leqembi's full approval and the future of Alzheimer's treatment
• With full Alzheimer's approval in hand, Eisai and Biogen kick off Leqembi's launch in earnest

 

See omnystudio.com/listener for privacy information.